Lyme's Hidden Threat: Experts Demand Research on Mother-to-Child Link

PORTOLA VALLEY, CA – April 09, 2026 – A coalition of international scientists and clinicians is issuing an urgent call for research into a long-suspected but critically understudied aspect of Lyme disease: its potential transmission from an infected mother to her unborn child. A new peer-reviewed paper in Frontiers in Medicine consolidates decades of evidence, from early case studies to modern biological understanding, to argue that the risk of congenital Lyme disease is a significant public health issue that has been neglected for too long.

The publication, stemming from a scientific summit convened by the Bay Area Lyme Foundation, points to a troubling gap in medical knowledge. With nearly half a million new Lyme disease cases diagnosed annually in the United States, the potential for adverse pregnancy outcomes—including miscarriage, stillbirth, and congenital infection—demands immediate and rigorous investigation, the authors contend.

“As an infectious disease pediatrician, I have seen firsthand the impact of Lyme disease in children and have suspected that the infection may have been passed from mother to child during pregnancy in a number of my patients, based on their medical histories,” said Dr. Charlotte Mao of the Bay Area Lyme Foundation, a co-author of the study. “The first case studies of mother-to-child transmission were observed in the 1980s, yet decades later, we still lack sufficient research and clear, evidence-based guidance on Lyme in pregnancy and adverse pregnancy outcomes.”

A Decades-Old Question

The possibility that Borrelia burgdorferi, the spiral-shaped bacterium that causes Lyme disease, could cross the placental barrier is not a new concept. Scientists have long known that other spirochetes, most notably Treponema pallidum which causes syphilis, can be transmitted from mother to fetus, leading to severe congenital disease. The first case reports suggesting similar transmission for Lyme disease emerged in the 1980s, shortly after the disease was identified.

Despite these early warnings and official acknowledgment from bodies like the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) that transmission is possible, the topic has remained in a scientific gray area. The new paper argues that this is not due to a lack of evidence, but a lack of focused, large-scale research.

“Collectively, my colleagues and I have been frustrated by limited funding and attention devoted to understanding Lyme disease in pregnancy,” stated Monica Embers, PhD, the paper's lead author and a professor at the Tulane National Biomedical Research Center. “By bringing together experts across disciplines, we were able to assess the existing evidence and identify the most critical research priorities needed to better understand mother-to-child transmission and protect the health of both mothers and their infants.”

The Clinical Crossroads: Guidance vs. Gaps

For expectant parents and their physicians, the current landscape is one of conflicting signals. Official guidelines from the CDC state that untreated Lyme disease during pregnancy can lead to placental infection and that while mother-to-fetus transmission is possible, it is considered rare. The standard protocol is to treat pregnant patients with antibiotics like amoxicillin or cefuroxime, after which, the CDC suggests, there is no increased risk of adverse birth outcomes. Doxycycline, the typical first-line treatment, is generally avoided due to potential effects on the fetus.

However, the authors of the Frontiers in Medicine article argue that this guidance rests on an unstable foundation of insufficient data. They point out that there are no comprehensive studies assessing the long-term developmental outcomes of children whose mothers were treated for Lyme disease during pregnancy. A 2022 survey study highlighted the stark reality: pregnancies affected by Lyme were associated with a higher rate of complications, from spontaneous abortion and stillbirth to a range of neonatal conditions, yet direct testing of newborns for the bacteria occurred in only 3% of at-risk cases.

The situation leaves clinicians in a difficult position, forced to counsel patients based on incomplete information. This uncertainty is a source of immense stress for families grappling with a Lyme diagnosis during what is already a vulnerable time.

A Roadmap for Answers

The new publication does more than just sound the alarm; it provides a detailed roadmap for the scientific community. The consensus, developed at a high-level meeting at the prestigious Banbury Center of Cold Spring Harbor Laboratory, calls for a multi-pronged research strategy. The primary recommendation is the creation of large, prospective studies that would follow pregnant individuals with Lyme disease through their pregnancies and systematically monitor the long-term health of their children.

Crucially, the experts emphasize the need to establish coordinated biorepositories. These would collect and store biological samples—from mothers, placentas, and infants—for current and future analysis. Such a resource would be invaluable for developing better diagnostic tests and understanding the biological mechanisms of transmission. The initiative, which brought together researchers from institutions like Tulane University and was funded by the Steven & Alexandra Cohen Foundation, represents a new, collaborative push to generate the real-world data that has been missing.

This push for research comes amid a complex funding environment. While public-private partnerships like the $25 million LymeX Innovation Accelerator, backed by the Department of Health and Human Services (HHS) and the Cohen Foundation, are injecting new resources into the field, other federal funding sources have faced cuts. Nonetheless, legislative champions continue to advocate for increased investment, reflecting a growing recognition of the disease's expanding public health footprint.

The Human Cost of Uncertainty

Behind the scientific debate and calls for funding are the human stories of families affected by the diagnostic uncertainty. Patient advocacy groups have for years been a repository for narratives of parents who suspect their children's unexplained, multi-systemic health issues are the result of congenital Lyme. These families often describe a painful diagnostic odyssey, navigating a medical system that lacks definitive answers for them.

The emotional and financial toll can be devastating. Without clear diagnostic markers for congenital Lyme or established treatment protocols, parents are left to piece together care, often facing skepticism and significant out-of-pocket expenses. The new research effort, with its emphasis on patient outcomes and long-term follow-up, offers a glimmer of hope that these families' experiences will be validated and addressed by rigorous science.

As Lyme disease continues its spread, becoming the most common vector-borne illness in the U.S., the questions surrounding its impact on pregnancy become ever more pressing. The work of Embers, Mao, and their colleagues is a declaration that the era of scientific neglect must end. By moving from scattered observations to systematic inquiry, the medical community may finally be able to provide the clarity and care that pregnant individuals and their children deserve.